newli
emerg
coronaviru
respons
current
pandem
result
one
million
infect
death
vaccin
therapeut
discoveri
effort
paramount
curb
pandem
spread
zoonot
viru
spike
glycoprotein
promot
entri
host
cell
main
target
neutral
antibodi
describ
multipl
monoclon
antibodi
target
identifi
memori
b
cell
sar
survivor
infect
one
antibodi
name
potent
neutral
sarscov
pseudovirus
well
authent
engag
bind
domain
use
cryoelectron
microscopi
bind
assay
show
recogn
glycancontain
epitop
conserv
within
sarbecoviru
subgenu
without
compet
receptor
attach
antibodi
cocktail
includ
along
antibodi
identifi
enhanc
neutral
may
limit
emerg
neutralizationescap
mutant
result
pave
way
use
antibodi
cocktail
prophylaxi
individu
high
risk
exposur
postexposur
therapi
limit
treat
sever
diseas
authorfund
right
reserv
reus
allow
without
permiss
biorxiv
preprint
coronaviru
entri
host
cell
mediat
transmembran
spike
glycoprotein
form
homotrim
protrud
viral
surfac
glycoprotein
compris
two
function
subunit
divid
b
c
domain
respons
bind
host
cell
receptor
promot
fusion
viral
cellular
membran
sarscov
belong
sarbecoviru
subgenu
glycoprotein
share
amino
acid
sequenc
ident
close
relat
bat
sarsrel
cov
sarsrcov
share
amino
acid
sequenc
ident
other
recent
demonstr
human
angiotensin
convert
enzym
function
receptor
case
sarscov
domain
b
b
receptor
bind
domain
rbd
bind
highaffin
possibl
contribut
current
rapid
transmiss
human
previous
propos
sarscov
coronaviru
glycoprotein
mediat
entri
host
cell
main
target
neutral
antibodi
focu
therapeut
vaccin
design
effort
trimer
extens
decor
nlink
glycan
import
protein
fold
modul
access
host
proteas
neutral
antibodi
cryoelectron
microscopi
cryoem
structur
two
distinct
function
state
along
cryoem
crystal
structur
b
complex
reveal
dynam
state
b
domain
provid
blueprint
design
vaccin
inhibitor
viral
entri
passiv
administr
monoclon
antibodi
mab
could
major
impact
control
pandem
provid
immedi
protect
complement
develop
prophylact
vaccin
acceler
develop
mab
pandem
set
could
reduc
month
compar
tradit
timelin
month
kelley
b
develop
monoclon
antibodi
pandem
speed
nat
biotechnol
press
recent
find
ansuvimab
safe
effect
treatment
symptomat
ebola
viru
infect
strike
exampl
success
use
mab
therapi
infecti
diseas
outbreak
previous
isol
potent
neutral
human
mab
memori
b
cell
individu
infect
sarscov
merscov
passiv
transfer
mab
protect
anim
challeng
variou
sarscov
isol
relat
cov
sarsrcov
well
merscov
structur
character
two
mab
complex
sarscov
merscov
authorfund
right
reserv
reus
allow
without
permiss
biorxiv
preprint
provid
molecularlevel
inform
mechan
viral
neutral
particular
mab
block
b
attach
host
receptor
covneutr
mab
act
function
mimick
receptorattach
promot
fusogen
conform
rearrang
anoth
mechan
sarscov
neutral
recent
describ
mab
bound
cryptic
epitop
access
least
two
three
b
domain
trimer
open
conform
howev
none
mab
neutral
identif
potent
neutral
mab
sar
survivor
previous
identifi
set
human
neutral
mab
individu
infect
sarscov
potent
inhibit
human
zoonot
sarscov
isol
character
potenti
crossreact
antibodi
perform
new
memori
b
cell
screen
use
peripher
blood
mononuclear
cell
collect
patient
describ
nineteen
mab
initi
screen
blood
draw
six
mab
new
screen
blood
draw
identifi
mab
broad
v
gene
usag
clonal
relat
tabl
eight
twenti
five
mab
bound
sarscov
transfect
cho
cell
valu
rang
ngml
ngml
respect
fig
b
mab
evalu
bind
sarscov
b
domain
well
prefusionstabil
merscov
cov
ectodomain
trimer
none
mab
studi
bound
prefus
merscov
ectodomain
trimer
indic
lack
reactiv
outsid
sarbecoviru
subgenu
extend
data
mab
recogn
sarscov
rbd
particular
bound
nanomolar
affin
b
domain
determin
biolay
interferometri
fig
extend
data
fig
unexpectedli
stain
cell
express
higher
level
express
sarscov
yet
interact
sarscov
ectodomain
trimer
rbd
construct
elisa
result
suggest
may
recogn
postfus
recent
propos
abund
surfac
authent
virus
fig
extend
data
biorxiv
preprint
evalu
neutral
potenc
crossreact
mab
carri
pseudoviru
neutral
assay
use
murin
leukemia
viru
mlv
pseudotyp
system
show
compar
neutral
potenc
sarscov
pseudovirus
wherea
neutral
sarscovmlv
weakli
neutral
sarscovmlv
extend
data
addit
neutral
sarscovmlv
isol
phase
epidem
valu
compris
ngml
partial
neutral
sarsrcov
fig
final
mab
potent
neutral
authent
ngml
fig
studi
mechan
neutral
character
complex
fab
fragment
prefus
stabil
ectodomain
trimer
use
singleparticl
cryoem
similar
previou
studi
apo
classif
cryoem
data
enabl
identif
two
structur
state
trimer
one
b
domain
open
close
trimer
determin
reconstruct
ectodomain
trimer
singl
open
b
domain
close
state
appli
symmetri
three
fab
bound
resolut
respect
fig
extend
data
fig
tabl
parallel
also
determin
crystal
structur
fab
resolut
assist
model
build
tabl
fab
bound
open
b
domain
weakli
resolv
cryoem
map
due
mark
conform
variabl
upward
point
b
domain
model
densiti
analysi
base
close
state
structur
recogn
proteinglycan
epitop
b
distinct
receptorbind
motif
epitop
access
open
close
state
explain
stoichiometr
bind
fab
trimer
fig
paratop
compos
six
cdr
loop
buri
surfac
area
interfac
b
electrostat
interact
hydrophob
contact
long
sit
atop
b
helix
compris
residu
also
contact
edg
b
fivestrand
bsheet
residu
overal
account
buri
surfac
area
fig
extend
epitop
interact
helix
span
residu
locat
near
authorfund
right
reserv
reus
allow
without
permiss
biorxiv
preprint
molecular
axi
sandwich
glycan
posit
contact
core
fucos
moieti
agreement
detect
corefucosyl
peptid
massspectrometri
lesser
extent
core
nacetylglucosamin
fig
latter
interact
buri
averag
surfac
stabil
oligosaccharid
resolv
much
larger
extent
apo
structur
structur
data
explain
crossreact
sarscov
residu
epitop
strictli
conserv
fig
extend
data
fig
conserv
substitut
except
wherea
semiconserv
substitut
agreement
compar
bind
affin
sarscov
fig
oligosaccharid
posit
also
conserv
virus
correspond
sarscov
previous
detect
corefucosyl
glycopeptid
mass
spectrometri
would
allow
similar
interact
fab
analysi
glycoprotein
sequenc
isol
report
date
indic
sever
mutat
occur
variabl
frequenc
ectodomain
extend
data
fig
mutat
aros
within
epitop
recogn
mab
final
contact
residu
show
high
degre
conserv
across
clade
sarbecoviru
human
anim
isol
extend
data
fig
collect
structur
data
indic
could
neutral
isol
circul
date
possibl
zoonot
sarbecovirus
cryoem
structur
bound
present
combin
structur
b
sarscov
b
complex
indic
fab
engag
epitop
distinct
receptorbind
motif
would
clash
upon
bind
figur
biolay
interferometri
analysi
fab
igg
bind
b
domain
ectodomain
trimer
confirm
absenc
competit
mab
bind
figur
extend
data
fig
biorxiv
preprint
investig
mechan
neutral
compar
sidebysid
transduct
presenc
either
fab
igg
experi
yield
compar
valu
nm
respect
indic
similar
potenc
igg
fab
fig
howev
igg
reach
neutral
wherea
fab
plateau
neutral
fig
result
indic
one
iggspecif
bival
mechan
trimer
crosslink
steric
hindranc
aggreg
virion
may
contribut
abil
fulli
neutral
pseudovirion
fcdepend
effector
mechan
nkmediat
antibodydepend
cell
cytotox
adcc
antibodydepend
cellular
phagocytosi
adcp
contribut
viral
control
infect
individu
observ
effici
adcc
stransfect
cell
wherea
mab
test
show
limit
activ
fig
extend
data
fig
find
might
relat
distinct
bind
orient
andor
posit
mab
fc
fragment
rel
fcgriiia
receptor
adcc
observ
use
nk
effector
cell
express
highaffin
fcgriiia
variant
affin
variant
fig
result
confirm
use
fcgriiia
cell
report
assay
fig
suggest
fc
engin
could
potenti
enhanc
activ
nk
cell
lowaffin
fcgriiia
variant
macrophag
dendrit
cellmedi
adcp
contribut
viral
control
clear
viru
infect
cell
stimul
cell
respons
via
present
viral
antigen
similar
adcc
result
mab
show
strongest
adcp
respons
fig
extend
data
fig
fcgriia
signal
howev
observ
fig
find
suggest
adcp
monocyt
depend
fcgriiia
fcgriia
engag
collect
result
demonstr
addit
potent
vitro
neutral
may
leverag
addit
protect
mechan
vivo
previous
shown
antivir
antibodi
gain
insight
epitop
recogn
panel
mab
use
structur
inform
escap
mutant
analysi
biolay
inteferometrybas
epitop
bin
map
antigen
site
present
authorfund
right
reserv
reus
allow
without
permiss
biorxiv
preprint
cov
b
domain
fig
extend
data
analysi
identifi
least
four
antigen
site
within
b
domain
sarscov
target
panel
mab
receptorbind
motif
target
term
site
site
ii
iii
defin
respect
two
site
bridg
mab
site
iv
defin
mab
given
lower
number
mab
crossreact
abl
identifi
site
iv
target
site
iiiii
target
fig
base
find
evalu
neutral
potenc
site
iv
mab
combin
either
site
ii
mab
site
iiiii
mab
although
alon
weakli
neutral
combin
either
mab
result
enhanc
neutral
potenc
compar
singl
mab
authent
fig
fig
synergist
effect
two
noncompet
antirbd
mab
alreadi
report
sarscov
data
extend
observ
provid
proofofconcept
use
mab
combin
prevent
control
summari
studi
identifi
human
mab
broad
neutral
activ
multipl
sarbecovirus
includ
via
recognit
highli
conserv
epitop
b
domain
compris
sarscov
furthermor
recruit
effector
mechan
synerg
weakli
neutral
mab
may
mitig
risk
viral
escap
data
indic
potenti
discov
potent
neutral
pansarbecoviru
mab
highlight
antigen
site
includ
vaccin
design
pave
way
support
prepared
futur
sarbecoviru
outbreak
bear
promis
effect
countermeasur
curtail
pandem
caus
fc
variant
increas
halflif
effector
function
enter
acceler
develop
path
toward
clinic
trial
authorfund
right
reserv
reus
allow
without
permiss
newli
emerg
coronaviru
respons
current
pandem
result
one
million
infect
death
vaccin
therapeut
discoveri
effort
paramount
curb
pandem
spread
zoonot
viru
spike
glycoprotein
promot
entri
host
cell
main
target
neutral
antibodi
describ
multipl
monoclon
antibodi
target
identifi
memori
b
cell
sar
survivor
infect
one
antibodi
name
potent
neutral
sarscov
pseudovirus
well
authent
engag
bind
domain
use
cryoelectron
microscopi
bind
assay
show
recogn
glycancontain
epitop
conserv
within
sarbecoviru
subgenu
without
compet
receptor
attach
antibodi
cocktail
includ
along
antibodi
identifi
enhanc
neutral
may
limit
emerg
neutralizationescap
mutant
result
pave
way
use
antibodi
cocktail
prophylaxi
individu
high
risk
exposur
postexposur
therapi
limit
treat
sever
diseas
coronaviru
entri
host
cell
mediat
transmembran
spike
glycoprotein
form
homotrim
protrud
viral
surfac
glycoprotein
compris
two
function
subunit
divid
b
c
domain
respons
bind
host
cell
receptor
promot
fusion
viral
cellular
membran
sarscov
belong
sarbecoviru
subgenu
glycoprotein
share
amino
acid
sequenc
ident
close
relat
bat
sarsrel
cov
sarsrcov
share
amino
acid
sequenc
ident
other
recent
demonstr
human
angiotensin
convert
enzym
function
receptor
case
sarscov
rang
ngml
ngml
respect
fig
b
mab
evalu
bind
sarscov
b
domain
well
prefusionstabil
merscov
cov
ectodomain
trimer
none
mab
studi
bound
prefus
merscov
ectodomain
trimer
indic
lack
reactiv
outsid
sarbecoviru
subgenu
extend
data
mab
recogn
sarscov
rbd
particular
bound
nanomolar
affin
b
domain
determin
biolay
interferometri
fig
extend
data
fig
unexpectedli
stain
cell
express
higher
level
express
sarscov
yet
interact
sarscov
ectodomain
trimer
rbd
construct
elisa
result
suggest
may
recogn
postfus
recent
propos
abund
surfac
authent
virus
fig
extend
data
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
molecular
axi
sandwich
glycan
posit
contact
core
fucos
moieti
agreement
detect
corefucosyl
peptid
massspectrometri
lesser
extent
core
nacetylglucosamin
fig
latter
interact
buri
averag
surfac
stabil
oligosaccharid
resolv
much
larger
extent
apo
structur
structur
data
explain
crossreact
sarscov
residu
epitop
strictli
conserv
fig
extend
data
fig
conserv
substitut
except
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
investig
mechan
neutral
compar
sidebysid
transduct
presenc
either
fab
igg
experi
yield
compar
valu
nm
respect
indic
similar
potenc
igg
fab
fig
howev
igg
reach
neutral
wherea
fab
plateau
neutral
fig
result
indic
one
iggspecif
bival
mechan
trimer
crosslink
steric
hindranc
aggreg
virion
may
contribut
abil
fulli
neutral
pseudovirion
fc
fragment
rel
fcgriiia
receptor
adcc
observ
use
nk
effector
cell
express
highaffin
fcgriiia
variant
affin
variant
fig
result
confirm
use
fcgriiia
cell
report
assay
fig
gain
insight
epitop
recogn
panel
mab
use
structur
inform
escap
mutant
analysi
biolay
inteferometrybas
epitop
bin
map
antigen
site
present
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
cov
b
domain
fig
extend
data
analysi
identifi
least
four
antigen
site
within
b
domain
sarscov
target
panel
mab
receptorbind
motif
target
term
site
site
ii
iii
defin
respect
two
site
bridg
mab
site
iv
defin
mab
given
lower
number
mab
crossreact
abl
identifi
site
iv
target
site
iiiii
target
fig
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
movi
frame
align
estim
microscop
contrasttransf
function
paramet
particl
pick
extract
carri
use
warp
particl
imag
extract
box
size
bin
yield
pixel
size
data
set
two
round
referencefre
classif
perform
use
cryosparc
select
welldefin
particl
imag
subsequ
two
round
classif
iter
angular
sampl
iter
local
search
iter
use
previous
report
close
structur
initi
model
carri
use
relion
without
impos
symmetri
separ
distinct
conform
refin
carri
use
nonuniform
refin
along
perparticl
defocu
refin
cryosparc
particl
imag
subject
bayesian
polish
perform
anoth
round
nonuniform
refin
cryosparc
follow
particl
defocu
refin
nonuniform
refin
jeffamin
crystal
cryoprotect
use
mother
liquor
solut
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
supplement
glycerol
dataset
collect
al
beamlin
process
resolut
space
group
use
mosflm
aimless
structur
fab
solv
molecular
replac
use
phaser
homolog
model
search
model
coordin
improv
complet
use
coot
refin
crystallograph
data
collect
refin
statist
shown
tabl
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
mab
ab
ribbon
diagram
bound
b
composit
model
gener
use
cryoem
structur
report
crystal
structur
bound
c
competit
mab
bind
sarscov
b
left
panel
b
right
panel
immobil
surfac
biosensor
incub
b
domain
alon
b
precomplex
mab
vertic
dash
line
indic
start
associ
mabcomplex
free
b
solidphas
neutral
sarscovmlv
fab
plot
nm
mean
shown
one
two
experi
shown
e
mabmedi
adcc
use
primari
nk
effector
cell
sexpress
expicho
target
cell
bar
graph
show
averag
area
curv
auc
respons
donor
genotyp
fcgriiia
two
independ
experi
f
activ
high
affin
low
affin
fcgriiia
measur
use
jurkat
report
cell
sexpress
expicho
target
cell
one
experi
one
two
measur
per
mab
g
mabmedi
adcp
use
cell
trace
violetlabel
pbmc
phagocyt
cell
sexpress
expicho
target
cell
bar
graph
show
averag
area
curv
auc
respons
four
donor
two
independ
experi
h
activ
fcgriia
measur
use
jurkat
report
cell
sexpress
expicho
target
cell
one
experi
one
two
measur
per
mab
fig
b
competit
mab
pair
bind
b
domain
cd
neutral
combin
equimolar
amount
mab
mab
cocktail
concentr
x
axi
individu
mab
tabl
characterist
antibodi
describ
studi
vh
vl
ident
refer
v
gene
ident
compar
germlin
imgt
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
